Vivione Biosciences Inc. Announces Management Changes
(firmenpresse) - DALLAS, TEXAS -- (Marketwired) -- 10/07/14 -- Vivione Biosciences Inc. ("Vivione" or the "Company") (TSX VENTURE: VBI), is pleased to announce that the TSX Venture Exchange (the "Exchange") has approved the extension of the expiry date of 12,000,000 common share purchase warrants (the "Warrants") issued to subscribers as part of the Company's prospectus financing which closed on April 19, 2013. The expiry dates of the Warrants have been extended for a period of one year from October 19, 2014 to October 14, 2015. All other terms of the Warrants remain the same. The Company will deliver a Notice of Amendment reflecting the amended expiry date to the registered holders of the Warrants.
About Vivione
Formed in 2006 in collaboration with the FDA, Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B system; an integrated system of hardware, software and chemical reagents that quickly and accurately identify, quantify and qualify bacteria and other pathogens in food safety, bio-therapeutics, clinical, industrial and oil & gas environments. For more information, visit .
Cautionary Statements
This news release contains "forward-looking statements" within the meaning of applicable securities laws. Although Vivione believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to Vivione. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. This news release contains forward-looking information relating to the commercialization and the development of the RAPID-B system and Vivione's business and growth. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this news release are made as of the date of this news release and, except as required by applicable law, Vivione does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. Vivione undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Vivione, or its financial or operating results or (as applicable), their securities.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Contacts:
Whitney Black
Edelman for Vivione
(214) 443-7553
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.10.2014 - 12:30 Uhr
Sprache: Deutsch
News-ID 341629
Anzahl Zeichen: 0
contact information:
Town:
DALLAS, TEXAS
Kategorie:
Advertising, PR and Marketing
Diese Pressemitteilung wurde bisher 230 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vivione Biosciences Inc. Announces Management Changes"
steht unter der journalistisch-redaktionellen Verantwortung von
Vivione Biosciences Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
